Humacyte Inc (HUMA)
7.05
-0.15
(-2.08%)
USD |
NASDAQ |
Jun 14, 16:00
6.77
-0.28
(-3.97%)
After-Hours: 20:00
Humacyte Research and Development Expense (Quarterly): 21.26M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 21.26M |
| December 31, 2023 | 20.18M |
| September 30, 2023 | 18.55M |
| June 30, 2023 | 20.54M |
| March 31, 2023 | 17.28M |
| December 31, 2022 | 14.96M |
| September 30, 2022 | 17.34M |
| June 30, 2022 | 14.65M |
| Date | Value |
|---|---|
| March 31, 2022 | 16.31M |
| December 31, 2021 | 16.25M |
| September 30, 2021 | 15.39M |
| June 30, 2021 | 14.57M |
| March 31, 2021 | 15.14M |
| December 31, 2020 | 13.20M |
| September 30, 2020 | 14.69M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
13.20M
Minimum
Dec 2020
21.26M
Maximum
Mar 2024
16.69M
Average
16.25M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 5.932M |
| Revance Therapeutics Inc | 14.39M |
| AN2 Therapeutics Inc | 14.66M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |